Matrix metalloproteinase-9 (MMP-9) is a gelatinase, which is a member of the MMPs family. We know that MMP-9 is not only an important gelatinase to regulate the extracellular matrix balance, but also one of the most closely related proteases to the pathogenesis of intracranial aneurysm. The purpose of this study is to investigate the relationship between MMP-9 gene polymorphism and intracranial aneurysm. In this paper, 98 patients who were admitted to a hospital from 2018 to 2019 were selected as the experimental group and the control group according to the relevant standards of intracranial aneurysms. The MMP-9 positive and MMP-9 absorbance values between the two groups were compared, so as to determine the concentration of MMP-9 between the two groups. In addition, the gene distribution and gene frequency analysis of the C-1562T promoter region of MMP-9 were carried out. The results showed that in the control group, the gene distribution frequency of CC type was 67% that of CT type was 31% that of TT type was 2%, that of the experimental group was 52%, and that of CT type was 44%. The results showed that there was a correlation between MMP-9 gene polymorphism and intracranial aneurysm.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14715/cmb/2022.68.1.3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design and early progress of the Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial.
Int J Stroke
January 2025
Medical University of South Carolina, Charleston, SC, USA.
Background: The usual antithrombotic treatment for symptomatic intracranial atherosclerotic stenosis (ICAS) consists of dual treatment with clopidogrel and aspirin for 90 days followed by aspirin alone but the risk of recurrent stroke remains high up to 12 months. The Comparison of Anticoagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) trial was designed to determine whether other combinations of dual antithrombotic therapy are superior to clopidogrel and aspirin.
Methods: CAPTIVA is an ongoing, prospective, double-blinded, three-arm clinical trial at over 100 sites in the United States and Canada that will randomize 1683 high-risk subjects with a symptomatic infarct attributed to 70-99% stenosis of a major intracranial artery to 12 months of treatment with (1) ticagrelor (180 mg loading dose, then 90 mg twice daily), (2) low-dose rivaroxaban (2.
Mechanical thrombectomy in elderly stroke patients with low ASPECTS: insights from STAR.
J Neurointerv Surg
January 2025
Department of Neurosurgery, Division of Neuroendovascular Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
Background: The elderly population (≥80 years) were underrepresented in recent trials of endovascular thrombectomy (EVT) for anterior circulation large vessel occlusion acute ischemic stroke (LVO-AIS) with low Alberta Stroke Program Early CT Score (ASPECTS) (≤5).
Methods: This study analyzed data from a prospectively maintained database of 37 thrombectomy centers. The primary cohort of the study comprised patients with LVO-AIS aged ≥80 who underwent EVT with ASPECTS≤5 from 2013 to 2023.
Competing pathways of intracranial aneurysm growth: linking regional growth distribution and hemodynamics.
J Neurosurg
January 2025
1Department of Bioengineering, George Mason University, Fairfax, Virginia.
Objective: The complex mix of factors, including hemodynamic forces and wall remodeling mechanisms, that drive intracranial aneurysm growth is unclear. This study focuses on the specific regions within aneurysm walls where growth occurs and their relationship to the prevalent hemodynamic conditions to reveal critical mechanisms leading to enlargement.
Methods: The authors examined hemodynamic models of 67 longitudinally followed aneurysms, identifying 88 growth regions.
Recurrence rate of intracranial aneurysms: a systematic review and a meta-analysis comparing craniotomy and endovascular coiling.
Neurosurg Rev
January 2025
Department of Neurosurgery, Sanya Central Hospital (Hainan Third People's Hospital）, No. 1154, Jiefang Road, Sanya City, Hainan Province, 572000, China.
Patients with intracranial aneurysm (IA) are at high risk of cerebral hemorrhage, which is associated with high mortality. Craniotomy or interventional endovascular coiling are common treatment methods in clinical practice, depending on the patient's condition. However, the recurrence rate of IA after either method remains unclear.
View Article and Find Full Text PDFIntracranial Aneurysms Treated with a Novel Coated Low-Profile Flow Diverter (p48 HPC)-A Single-Center Experience and an Illustrative Case Series.
Brain Sci
January 2025
Department of Diagnostic and Interventional Neuroradiology, School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany.
The p48 MW HPC is a novel low-profile flow diverter covered by a hydrophilic polymer coating with antithrombogenic properties, which may reduce ischemic complications and enable a single antiplatelet therapy after insertion of the stent. In this single-center experience, we describe the efficacy of this device, focusing on the illustration of different therapeutic indications and the outcome in various clinical settings with regard to vessel anatomy, bleeding state, and aneurysm configuration. We retrospectively reviewed our database for all patients being treated with a p48 MW HPC flow diverter between February 2019 and July 2021.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!